Edward M. Messing

Q: What Schools Are Affiliated With Edward M. Messing

Edward M. Messing is affiliated with the following schools: University of Western Ontario, Stanford University, China Medical University , University of Colorado, University of Rochester

Edward M. Messing's AcademicInfluence.com Rankings

Edward M. Messing

Philosophy

#6236

World Rank

#9238

Historical Rank

Logic

#3420

World Rank

#4574

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Edward M. Messing Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Edward M. Messing's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. (2009) (940)
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. (2006) (887)
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. (2006) (873)
Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. (1999) (726)
Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. (2012) (436)
Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. (2014) (427)
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. (2005) (421)
Interstitial cystitis: early diagnosis, pathology, and treatment. (1978) (377)
Promotion of bladder cancer development and progression by androgen receptor signals. (2007) (357)
Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. (1996) (321)
Androgen deprivation therapy for prostate cancer: Current status and future prospects (2004) (320)
Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. (2003) (288)
Detection of bladder cancer using a point-of-care proteomic assay. (2005) (277)
A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. (2003) (274)
Sex and racial differences in bladder cancer presentation and mortality in the US (2009) (269)
Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. (1995) (227)
Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. (2006) (217)
Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. (2007) (216)
Is there a favorable subset of patients with prostate cancer who develop oligometastases? (2004) (215)
Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. (2003) (214)
Androgen receptor is a tumor suppressor and proliferator in prostate cancer (2008) (203)
Quantitative characterization of viscoelastic properties of human prostate correlated with histology. (2008) (190)
Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder (2012) (185)
VHL protein‐interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF‐1α (2005) (184)
Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. (1992) (184)
Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. (1990) (184)
Re: Prevalence of Kidney Stones in the United States Scales CD Jr, Smith AC, Hanley JM, Saigal CS, Urologic Diseases in America Project (2012) (182)
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. (2005) (172)
Gender, racial and age differences in bladder cancer incidence and mortality. (2004) (165)
Long‐term outcome of hematuria home screening for bladder cancer in men (2006) (164)
Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression. (2014) (161)
Ubiquitination of a Novel Deubiquitinating Enzyme Requires Direct Binding to von Hippel-Lindau Tumor Suppressor Protein* (2002) (156)
Activation of Ras/Erk Pathway by a Novel MET-interacting Protein RanBPM* (2002) (155)
Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells (2002) (154)
Home screening for hematuria: results of a multiclinic study. (1992) (151)
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial (2018) (151)
The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks. (1987) (148)
Δ5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells (1998) (147)
Prostate cancer in the elderly (2012) (138)
A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. (2005) (137)
Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. (1996) (137)
Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. (1995) (129)
The diagnosis of interstitial cystitis. (1987) (129)
Sequelae of radical prostatectomy. (1994) (123)
Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. (2002) (121)
A prospective study of quantification of urinary incontinence and quality of life in patients undergoing radical retropubic prostatectomy. (1996) (119)
Localization of androgen receptor expression in human bone marrow (2001) (117)
Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview. (2012) (116)
Epidermal growth factor--interactions with normal and malignant urothelium: in vivo and in situ studies. (1987) (115)
Urological Complications in 210 Consecutive Simultaneous Pancreas‐Kidney Transplants with Bladder Drainage (1993) (113)
Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi‐institutional study (2011) (112)
Molecular mechanisms and pathways in bladder cancer development and progression. (2000) (107)
Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710) (2010) (105)
Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age (1989) (105)
Living Related and Unrelated Donors for Kidney Transplantation A 28‐Year Experience (1995) (105)
In vivo motion and force measurement of surgical needle intervention during prostate brachytherapy. (2006) (104)
Bladder cancer in renal transplant recipients. (1997) (98)
Hematuria home screening: repeat testing results. (1995) (96)
Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway. (2005) (95)
Epidemiology and Natural History (2015) (95)
Associations among cystoscopic findings and symptoms and physical examination findings in women enrolled in the Interstitial Cystitis Data Base (ICDB) Study. (1997) (93)
Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? (2009) (91)
Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel—Lindau protein (2003) (90)
The VHL protein recruits a novel KRAB‐A domain protein to repress HIF‐1α transcriptional activity (2003) (87)
DO MIXED HISTOLOGICAL FEATURES AFFECT SURVIVAL BENEFIT FROM NEOADJUVANT PLATINUM‐BASED COMBINATION CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER? (2011) (86)
Microscopically controlled surgery in the treatment of carcinoma of the penis. (1985) (86)
Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. (2005) (81)
High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. (1989) (80)
Near infrared fluorescence imaging after intravenous indocyanine green: initial clinical experience with open partial nephrectomy for renal cortical tumors. (2012) (79)
Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric Magnetic Resonance Imaging: Correlation with Final Histopathology (2017) (79)
A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients (2012) (78)
Intraoperative optimized inverse planning for prostate brachytherapy: early experience. (1999) (78)
Robot-Assisted Prostate Brachytherapy (2006) (77)
Prostate cancer: three-dimensional sonoelastography for in vitro detection. (2005) (77)
Multispectral Photoacoustic Imaging of Prostate Cancer: Preliminary Ex-vivo Results (2013) (77)
Hematuria screening for bladder cancer. (1990) (77)
Treatment of nonmuscle invading bladder cancer: Do physicians in the United States practice evidence based medicine? (2009) (76)
Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes. (2015) (76)
Sequelae of definitive radiation therapy for prostate cancer localized to the pelvis. (1994) (73)
Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1 (2008) (72)
The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. (2008) (71)
Defects of prostate development and reproductive system in the estrogen receptor-alpha null male mice. (2009) (71)
Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer (2007) (71)
Effects of Velocity Modulation during Surgical Needle Insertion (2005) (69)
Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes, and growth factors. (1992) (68)
Inhibition of the Akt, cyclooxygenase‐2, and matrix metalloproteinase‐9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer (2005) (67)
Normal and malignant human urothelium: in vitro effects of epidermal growth factor. (1987) (67)
A Comprehensive Analysis of Cribriform Morphology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy Correlated with Radical Prostatectomy Specimens (2018) (65)
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. (2019) (65)
Testicular microlithiasis: a review and its association with testicular cancer. (2004) (65)
Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy. (1989) (64)
Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. (2013) (64)
Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo. (2014) (62)
CT in detecting urinary tract calculi: influence on patient imaging and clinical outcomes. (2002) (62)
Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer (2016) (60)
Bladder cancer: natural history, tumor markers, and early detection strategies. (1997) (60)
Robot-assisted and laparoscopic partial nephrectomy with near infrared fluorescence imaging. (2012) (59)
Long-term outcome of patients with a negative work-up for asymptomatic microhematuria. (2006) (59)
The management of a clinical t1b renal tumor in the presence of a normal contralateral kidney. (2013) (56)
Estrogen receptor α in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3. (2014) (56)
Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. (2002) (56)
Long-term experience with pentosanpolysulfate in interstitial cystitis. (1998) (55)
Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. (1995) (55)
Evaluation of robotic needle insertion in conjunction with in vivo manual insertion in the operating room (2005) (53)
The SPRY Domain-containing SOCS Box Protein 1 (SSB-1) Interacts with MET and Enhances the Hepatocyte Growth Factor-induced Erk-Elk-1-Serum Response Element Pathway* (2005) (53)
Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort. (2015) (52)
Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality (2011) (52)
Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder (2012) (51)
Bladder cancer in the elderly patient: challenges and solutions (2015) (50)
Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta‐analysis of eight cohort studies (2013) (50)
Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. (2014) (49)
Phase III Randomized Study of Adjuvant Radiation Therapy versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG 8794) (2005) (49)
The BCG Shortage (2017) (49)
Prostate‐specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation (2012) (49)
Robotic system for prostate brachytherapy (2007) (48)
Immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: At 10 years results of EST3886. (2004) (47)
Micropapillary bladder cancer: current treatment patterns and review of the literature. (2014) (46)
Role of lymphadenectomy in the treatment of renal cell carcinoma. (1993) (45)
A novel MET-interacting protein shares high sequence similarity with RanBPM, but fails to stimulate MET-induced Ras/Erk signaling. (2004) (45)
A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D. (2012) (44)
Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG‐ACRIN 2805) Adjuvant Trial (2018) (44)
Nonseminomatous germ cell tumor of the testicle: does extensive staging of the primary tumor predict the likelihood of metastatic disease? (1986) (44)
The correlation between the loss of chromosome 14q with histologic tumor grade, pathologic stage, and outcome of patients with nonpapillary renal cell carcinoma (1996) (44)
Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer (2016) (44)
Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer (2017) (44)
Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’ (2015) (44)
Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. (1996) (43)
Growth factors and bladder cancer: clinical implications of the interactions between growth factors and their urothelial receptors. (1992) (43)
Impact of bladder cancer on health related quality of life in 1,476 older Americans: a cross-sectional study. (2014) (43)
Sex differences in incidence and mortality of bladder and kidney cancers: national estimates from 49 countries. (2014) (42)
Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. (2005) (42)
Automated treatment planning engine for prostate seed implant brachytherapy. (1999) (42)
Bladder cancer extracellular vesicles drive tumorigenesis by inducing the unfolded protein response in endoplasmic reticulum of nonmalignant cells (2018) (41)
Effectiveness and safety of extended-duration prophylaxis for venous thromboembolism in major urologic oncology surgery. (2015) (41)
A molecular genetic model of human bladder carcinogenesis. (1993) (41)
BILITRANSLOCASE (BTL) IS IMMUNOLOCALISED IN PROXIMAL AND DISTAL RENAL TUBULES AND ABSENT IN RENAL CORTICAL TUMORS ACCURATELY CORRESPONDING TO INTRAOPERATIVE NEAR INFRARED FLUORESCENCE (NIRF) EXPRESSION OF RENAL CORTICAL TUMORS USING INTRAVENOUS INDOCYANINE GREEN (ICG) (2008) (40)
Healthcare economics of bladder cancer: cost-enhancing and cost-reducing factors (2008) (40)
Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients. (2016) (38)
Multi‐institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12‐core systematic biopsy (2018) (38)
Murine hybridoma antibodies against human transitional carcinoma-associated antigens. (1984) (37)
SIU–ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer (2019) (37)
Are we doing "better"? The discrepancy between perception and practice of enhanced recovery after cystectomy principles among urologic oncologists. (2016) (37)
Chromosome 9 monosomy by fluorescence in situ hybridization of bladder irrigation specimens is predictive of tumor recurrence. (1999) (36)
Increased Expression of Corepressors in Aggressive Androgen-Independent Prostate Cancer Cells Results in Loss of 1α,25-Dihydroxyvitamin D3 Responsiveness (2007) (36)
Needle Insertion Force Estimation Model using Procedure-specific and Patient-specific Criteria (2006) (36)
Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette‐Guérin (2009) (36)
Assessment of murine bladder permeability with fluorescein: validation with cyclophosphamide and protamine. (2001) (35)
Quality Improvement in Cystectomy Care with Enhanced Recovery (QUICCER) study (2017) (35)
Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells. (1994) (35)
Automated noninvasive measurement of cyclophosphamide-induced changes in murine voiding frequency and volume. (2001) (34)
Recovery of epidermal growth factor in voided urine of patients with bladder cancer. (1994) (34)
DNA cytometry and chromosome 9 aberrations by fluorescence in situ hybridization of irrigation specimens from bladder cancer patients. (1998) (34)
DBCCR1 mediates death in cultured bladder tumor cells (2004) (34)
Regulation of receptor for activated C kinase 1 protein by the von Hippel–Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness (2011) (32)
Automatic localization of implanted seeds from post-implant CT images. (2003) (31)
The burden of bladder cancer in men and women: analysis of the years of life lost (2012) (31)
Female bladder cancer: incidence, treatment, and outcome (2010) (30)
Androgen deprivation therapy for prostate cancer (2008) (30)
Penile Merkel cell carcinoma. (1995) (30)
Redo retroperitoneal lymphadenectomy for germ cell tumor. (1993) (30)
Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells. (1994) (30)
E-selectin ligand-1 controls circulating prostate cancer cell rolling/adhesion and metastasis (2014) (29)
Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression (2015) (29)
1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer (2013) (29)
Bladder cancer screening. (1996) (29)
Higher expression of peroxisome proliferator-activated receptor γ or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasion. (2013) (28)
Decreased bladder cancer growth in parous mice. (2008) (28)
Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men (2011) (28)
Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. (2019) (28)
Grade progression and regression in recurrent urothelial cancer. (2003) (27)
Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder. (1991) (27)
Interstitial cystitis antiproliferative factor (APF) as a cell-cycle modulator (2004) (27)
Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression (2012) (26)
Long-term outcome of home dipstick testing for hematuria (2008) (26)
Identifying additional lymph nodes in radical cystectomy lymphadenectomy specimens (2012) (26)
Serum-free medium for the in vitro growth of normal and malignant urinary bladder epithelial cells. (1982) (26)
The expression and actions of androgen receptor in upper urinary tract urothelial carcinoma (UUTUC) tissues and the primary cultured cells (2013) (26)
Historical and contemporary perspectives on cribriform morphology in prostate cancer (2018) (25)
Perineural invasion by prostate cancer on MR/US fusion targeted biopsy is associated with extraprostatic extension and early biochemical recurrence after radical prostatectomy. (2017) (25)
Spontaneous Throivibosis of Left Sperivcatic Vein: Report of 2 Cases (1985) (24)
Transrectal sonography in prostate evaluation. (2006) (24)
Bilateral rectus femoris pedicle flaps for detrusor augmentation in the prune belly syndrome. (1985) (24)
In-vivo Measurement of Surgical Needle Intervention Parameters: A Pilot Study (2006) (24)
Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor β/IL-1/c-MET signals. (2018) (24)
Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study. (1995) (24)
Workshop on imaging science development for cancer prevention and preemption. (2006) (23)
IMMEDIATE HORMONAL THERAPY VS. OBSERVATION FOR NODE POSITIVE PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY AND PELVIC LYMPHADENECTOMY: A RANDOMIZED PHASE III EASTERN COOPERATIVE ONCOLOGY GROUP/INTER GROUP TRIAL (1999) (23)
Normal and malignant human urothelium: in vitro response to blockade of polyamine synthesis and interconversion. (1988) (22)
Prostate‐specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system (2012) (22)
Complication of Clorpactin WCS90 therapy for interstitial cystitis. (1979) (22)
Increased expression of the acid sphingomyelinase-like protein ASML3a in bladder tumors. (2002) (22)
Re: Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. (2007) (22)
Methods for prostate stabilization during transperineal LDR brachytherapy (2008) (22)
Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma. (2021) (22)
The timing of hormone therapy for men with asymptomatic advanced prostate cancer. (2003) (21)
Perioperative methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for poor risk transitional cell carcinoma of the bladder: an Eastern Cooperative Oncology Group pilot study. (1990) (21)
Growth stimulating activity produced by human bladder cancer cells. (1984) (21)
Real-time US versus CT determination of pubic arch interference for brachytherapy. (2001) (21)
Epidermal growth factor and its receptor: Markers of— and targets for—chemoprevention of bladder cancer (1992) (20)
Cultures of normal human urothelial cells from ureters of perfused cadaver transplant kidneys. (1984) (20)
Bilateral Testicular Epidermoid Cysts (2011) (20)
Age as a predictor of an aggressive clinical course for superficial bladder cancer in men (1992) (20)
The correlation between the loss of chromosome 14q with histologic tumor grade, pathologic stage, and outcome of patients with nonpapillary renal cell carcinoma. (1996) (20)
Pelvic pain following radical retropubic prostatectomy: a prospective study. (1997) (19)
Low-dose difluoromethylornithine and polyamine levels in human prostate tissue. (1999) (19)
Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria (2009) (19)
Complications associated with extraperitoneal robot-assisted radical prostatectomy using the standardized Martin classification. (2013) (18)
Microscopic invasion of perivesical fat by urothelial carcinoma: implications for prognosis and pathology practice. (2010) (18)
Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men (2013) (18)
Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques (1998) (17)
Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy. (2003) (17)
Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged? (2008) (17)
Spontaneous thrombosis of left spermatic vein: report of 2 cases. (1985) (17)
Markers of detection. (2007) (17)
Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology Re: Do Mixed Histological Features Affect Survival Benefit from Neoadjuvant Platinum-Based Combination Chemotherapy in Patients with Locally Advanced Bladder Cancer? A Secondary Analysis of Southwest Oncology Group-Directed Intergr (2011) (16)
Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer? (2005) (16)
Current state of screening for bladder cancer (2007) (16)
Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated Gαi protein/MAPK/MMP9 intracellular signaling (2019) (16)
A real-time prostate cancer detection technique using needle insertion force and patient-specific criteria during percutaneous intervention. (2009) (16)
Stones in orthotopic, non-obstructing ureteroceles. (1979) (16)
Hypertension and post-traumatic renal arteriovenous fistula: demonstration of unilaterally elevated renin secretion. (1976) (16)
Role of frozen section analysis of testicular/paratesticular fibrous pseudotumours: a five-case experience. (2011) (15)
Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their disease. (2009) (15)
Chemotherapy of Bladder Cancer (1985) (15)
Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer (2016) (15)
A real-time prostate cancer detection technique using needle insertion force and patient-specific criteria during percutaneous intervention. (2009) (15)
Automated noninvasive measurement of cyclophosphamide-induced changes in murine micturition frequency and volume and demonstration of pharmacologic sensitivity. (2001) (15)
Local Recurrence Following Resection of Intermediate-High Risk Non-metastatic Renal Cell Carcinoma: An Anatomic Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. (2020) (15)
Automatic segmentation of prostate boundaries in transrectal ultrasound (TRUS) imaging (2002) (14)
Prostate and bladder cancer screening. (1998) (14)
Optical property measurements establish the feasibility of photodynamic therapy as a minimally invasive intervention for tumors of the kidney (2012) (14)
Semi-automated Needling and Seed Delivery Device for Prostate Brachytherapy (2006) (14)
Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. (2009) (14)
Early detection and measurement of urothelial tumors in mice. (2006) (14)
Early diagnosis and screening (2007) (13)
Early Diagnosis, Pathology, and Treatment (1978) (13)
Robotic system for prostate brachytherapy. (2007) (13)
Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. (2010) (13)
881: Long-Term Outcome of Hematuria Home Screening for Bladder Cancer (BC) (2006) (13)
Tenascin-C expression in the lymph node pre-metastatic niche in muscle-invasive bladder cancer (2021) (13)
1665: Adjuvant Radiotherapy for Pathologic T3 Prostate Cancer: Results of a Randomized, Prospective Clinical Trial with Metastasis-Free Survival Endpoint (2005) (13)
ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals (2019) (13)
Rate of Symptomatic Lymphocele Formation After Extraperitoneal vs Transperitoneal Robot-Assisted Radical Prostatectomy and Bilateral Pelvic Lymphadenectomy. (2017) (12)
Cautery artifact understages urothelial cancer at initial transurethral resection of large bladder tumours. (2017) (12)
The Prognostic Significance of S–Phase Analysis in Stage Ta/T1 Bladder Cancer (2000) (12)
Bouquet brachytherapy: feasibility and optimization of conically spaced implants. (2005) (12)
A Case Series of Transformation of Teratoma to Primitive Neuroectodermal Tumor: Evolving Management of a Rare Malignancy (2014) (12)
Extraperitoneal vs Transperitoneal Robot-Assisted Radical Prostatectomy in the Setting of Prior Abdominal or Pelvic Surgery. (2017) (12)
Non-bladder cancer mortality in patients with urothelial cancer of the bladder. (2013) (11)
Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression (2017) (11)
Chemoprevention of bladder cancer (2006) (11)
Radical versus partial nephrectomy for a small renal mass: does saving nephrons save lives? (2013) (11)
338 PROSTATE CANCER IN THE ELDERLY FREQUENCY OF ADVANCED DISEASE AT PRESENTATION AND DISEASE-SPECIFIC MORTALITY (2012) (11)
Loss of the CDKN2A/p16 locus detected in bladder irrigation specimens by fluorescence in situ hybridization. (1997) (11)
Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. (2019) (10)
Controversies surrounding lymph node dissection for prostate cancer. (2010) (10)
Correlation between N-acetyltransferase activities in uroepithelia and in vivo acetylator phenotype. (1992) (10)
Exploratory Subgroup Analyses of Renal Function and Overall Survival in European Organization for Research and Treatment of Cancer randomized trial of Nephron-sparing Surgery Versus Radical Nephrectomy. (2017) (10)
Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy (2016) (10)
Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. (2020) (10)
Psychological and mood disturbance associated with the diagnosis and treatment of testis cancer and other malignancies. (1990) (10)
A randomized trial of 2% lidocaine gel versus plain lubricating gel for minimizing pain in men undergoing flexible cystoscopy. (2013) (10)
Continuous bladder infusion methods for studying voiding function in the ambulatory mouse. (2002) (10)
Methodology to study the three-dimensional spatial distribution of prostate cancer and their dependence on clinical parameters (2015) (9)
Hybrid dosimetry: feasibility of mixing angulated and parallel needles in planning prostate brachytherapy. (2006) (9)
BCAN Think Tank session 3: Prevention of bladder cancer. (2010) (9)
Evaluation of the UroVysion™ Test to Predict Recurrence and/or Progression of Disease After BCG for Primary High Grade Non-Muscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial. (2019) (9)
Early versus late hormonal therapy for prostate cancer (2004) (9)
Molecular Landscape of Non-Muscle Invasive Bladder Cancer (2018) (9)
Proliferation-independent growth factor modulation of the radiation sensitivity of human prostate cells. (1995) (8)
Initial observations of reduced uroflow in transgenic adenocarcinoma of murine prostate. (2006) (8)
Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. (2015) (8)
258: Intraoperative Visualization of Cavernous Nerves Using Near Infrared Fluorescence of Indocyanine Green in the Rat (2006) (8)
Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation. (2020) (8)
The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing. (2012) (8)
Financial Toxicity of Having Bladder Cancer (2018) (8)
Antibiotic prophylaxis at the time of catheter removal after radical prostatectomy: A prospective randomized clinical trial. (2019) (8)
TR4 NUCLEAR RECEPTOR PROMOTES CLEAR CELL RENAL CELL CARCINOMA (CCRCC) VASCULOGENIC MIMICRY (VM) FORMATION AND METASTASIS VIA ALTERING THE MIR490‐3P/VIMENTIN SIGNALS: MP88‐08 (2018) (7)
Perspectives on prostate cancer diagnosis and treatment: a roundtable. (2001) (7)
Uroflow in murine urethritis. (2004) (7)
Why should we increase public awareness of bladder cancer, and how can we do it? (2008) (7)
Bladder cancer incidence and mortality in patients treated with radiation for uterine cancer (2014) (7)
Node positive renal cell cancer. Who can be helped? (2007) (6)
Method for assuring accuracy of bone biopsy using technetium 99 bone scan (1987) (6)
Efficacy of Prostate Stabilizing Techniques during Brachytherapy Procedure (2006) (6)
Extraperitoneal vs. transperitoneal robot-assisted radical prostatectomy in patients with a history of prior inguinal hernia repair with mesh (2017) (6)
TRAIL-coated leukocytes to kill circulating tumor cells in the flowing blood from prostate cancer patients (2021) (6)
A propspective clinical trial of difluoromethylornithine (DFMO) in patients with resected superficial bladder cancer (1992) (6)
Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study. (1996) (6)
MP65-17 CYSTECTOMY ENHANCED RECOVERY PATHWAY: REDUCTION IN LENGTH OF STAY WITHOUT INCREASED MORBIDITY OR READMISSIONS (2015) (6)
Timing hormonal therapy in prostate cancer. (2002) (5)
BCAN Think Tank session 2: Molecular detection of bladder cancer: the path to progress. (2010) (5)
The conundrum of recurrent low-grade tumours: to treat or to observe? (2018) (5)
Reply to prostate‐specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation (2012) (5)
Overall Survival after Partial Versus Radical Nephrectomy for a Small Renal Mass: Systematic Review of Observational Studies (2014) (5)
Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging. (2019) (5)
Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer (2016) (5)
INSTITUTIONAL LEARNING CURVE ASSOCIATED WITH IMPLEMENTATION OF A MR/US FUSION BIOPSY PROGRAM USING PIRADS VERSION 2: FACTORS THAT INFLUENCE SUCCESS: MP03‐11 (2017) (5)
Words of wisdom. Re: Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. (2012) (5)
Lack of Low-risk Pathologic Findings in SWOG 8794 (2009) (5)
Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy (2017) (5)
Radioactive seed immobilization techniques for interstitial brachytherapy (2008) (5)
Clinical Observation and Modeling of Postimplant Seed Displacement for Prostate Brachytherapy (2005) (5)
A method to minimize puncturing force and organ deformation (2006) (5)
Lost and now found: retained straight catheter for 20 years. (2011) (5)
Bladder tumor markers. (2006) (4)
Surgical readmissions: results of integrating pre‐, peri‐ and postsurgical care (2016) (4)
Three-dimensional fusion of prostate histology with sonoelastography images (2003) (4)
Estrogen Receptor Alpha Prevents Bladder Cancer Development via INPP4B inhibited Akt Pathway in vitro and in vivo (2014) (4)
Early stage bladder cancer. (1987) (4)
Vivo motion and force measurement of surgical needle intervention during prostate brachytherapy. (2006) (4)
Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy (2017) (4)
V8-01 FULL PROCEDURAL SIMULATION FOR TRANSURETHRAL RESECTION OF BLADDER TUMORS (TURBT) USING 3-D PRINTING TECHNOLOGY. (2016) (4)
Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2‐expressing tumors (2002) (4)
PD66-01 IMMEDIATE POST TURB INTRAVESICAL GEMCITABINE: A COST COMPARISON BASED ON SWOG S0337 (2018) (4)
Institutional Learning Curve Associated with Implementation of a Magnetic Resonance/Transrectal Ultrasound Fusion Biopsy Program Using PI‐RADS™ Version 2: Factors that Influence Success (2018) (3)
Diagnosis of Bladder Cancer (2001) (3)
EDITORIAL: INTERSTITIAL CYSTITIS-A LIGHT AT THE END OF THE TUNNEL? (1999) (3)
Inducible expression of catalytically active type 1 serine/threonine protein phosphatase in a human carcinoma cell line (2003) (3)
1455: Immediate VS Delayed Hormonal Therapy (HT) in Patients with Nodal Positive (N+) Prostate Cancer Who Had Undergone Radical Prostatectomy (RP) + Pelvic Lymphadenectomy (LND): Results of Central Pathology Review (CPR) (2004) (3)
Adjuvant therapy for genitourinary cancer. (1981) (3)
NEAR INFRARED FLUORESCENCE OF INTRAVENOUS INDOCYANINE GREEN FOR INTRAOPERATIVE IMAGING OF RENAL CORTICAL TUMORS: A COMPLETED FEASIBILITY STUDY (2008) (3)
Detection, diagnosis, and natural history of bladder cancer (1994) (3)
Abstract 5475: Cancer exosome promotes cisplatin resistance In bladder cancer and inhibition of exosome sensitizes bladder cancer cells to cisplatin chemotherapy (2015) (3)
Improving Rates of Immediate Postoperative Intravesical Chemotherapy with Gemcitabine for Low-Grade Bladder Cancer: An Implementation Analysis (2021) (3)
Lymphocele after retroperitoneal node dissection for testis tumor (1986) (3)
Effect of angiotensin converting enzyme inhibition on the Doppler waveform in dogs with renal artery stenosis. (1999) (3)
The role of urinary cytology when diagnostic workup is suspicious for upper tract urothelial carcinoma but tumour biopsy is nonconfirmatory. (2017) (3)
Pelvic Floor Organ Prolapse After Radical Cystectomy in Patients With Uroepithelial Carcinoma. (2019) (2)
1708 DO MIXED HISTOLOGIC FEATURES AFFECT SURVIVAL BENEFIT FROM NEO-ADJUVANT PLATINUM-BASED COMBINATION CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER? (2010) (2)
MP24-15 MR/US FUSION TARGETED BIOPSY FAILED TO DETECT PROSTATE CANCER: ROLE OF CONFIRMMDX® AS AN ADJUNCT (2019) (2)
Gleason score upgrade among 10,282 men who underwent surgery as initial treatment in 2010: A population-based study. (2014) (2)
Re: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? (2003) (2)
Editorial: Interstitial Cystitis (1994) (2)
Risk of second cancer among young prostate cancer survivors (2021) (2)
MP49-02 DIFFERENTIATION BETWEEN MALIGNANT, BENIGN PROSTATIC HYPERPLASIA AND NORMAL PROSTATE TISSUE USING FREQUENCY ANALYSIS OF MULTISPECTRAL PHOTOACOUSTIC IMAGES (2014) (2)
Cost‐Effectiveness of Extended Duration Venous Thromboembolism Prophylaxis in High Risk Urological Oncology Surgical Patients (2016) (2)
A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer. (2021) (2)
389 EXPRESSION OF ANDROGEN AND ESTROGEN RECEPTORS AND ITS PROGNOSTIC SIGNIFICANCE IN UROTHELIAL NEOPLASM OF THE URINARY BLADDER (2012) (2)
The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020? (2020) (2)
Bladder Cancer Extracellular Vesicles Elicit a CD8 T Cell-Mediated Antitumor Immunity (2022) (2)
Computer Assisted Radiation Therapy (2008) (2)
Association between copper transporter receptor 1(CTR1) expression and pathologic outcomes in cisplatin (Pt)-treated bladder cancer (BC) patients. (2014) (2)
Platinum concentration in bladder tissue treated with neoadjuvant chemotherapy and pathologic response. (2015) (2)
ROBOTIC NEEDLE INSERTION IN SOFT MATERIAL PHANTOMS : AN EVALUATION OF THE PROPERTY OF COMMONLY USED MATERIALS (2005) (2)
Reply from Authors re: R. Houston Thompson. Partial Versus Radical Nephrectomy: The Debate Regarding Renal Function Ends While the Survival Controversy Continues. Eur Urol 2014;65:378–9 (2014) (2)
Recontacting subjects in mutagen exposure monitoring studies. (1986) (2)
Sci‐PM Fri ‐ 05: Effects of coating on friction force during needle insertion in soft materials (2005) (2)
LAPAROSCOPIC PELVIC LYMPHADENECTOMY WITH REAL TIME LYMPHATIC IMAGING USING NEAR INFRARED FLUORESCENCE (NIRF) CAMERAS (2009) (2)
Bladder cancer risk: Use of PLCO and NLST to identify a suitable screening cohort. (2014) (2)
Use of Angiotensin Converting Enzyme Inhibitors is Associated with Reduced Risk of Late Bladder Toxicity Following Radiotherapy for Prostate Cancer. (2022) (2)
Checkpoint Inhibitors for Advanced Bladder Cancer (2016) (2)
MP39-11 BLADDER CANCER EXOSOMES CONTAIN TUMOR-ASSOCIATED MRNA AND LONG NON-CODING RNA AND FACILITATE TUMOR PROGRESSION (2014) (2)
The Need for Survivorship Care in Genitourinary Cancers: Considerations from SUO and LUGPA (2016) (2)
Interactions of Malignant and Normal Human Urothelial Cells with Epidermal Growth Factor (1987) (2)
625: Bert-Hogg-Dubé (BHD) Tumor Suppressor Expression in Sporadic Renal Cell Carcinomas (2005) (2)
522 EXPRESSION OF ANDROGEN AND ESTROGEN RECEPTORS AND ITS PROGNOSTIC SIGNIFICANCE IN HIGH-GRADE UROTHELIAL CARCINOMA OF THE BLADDER (2011) (1)
Receptor-negative Prostate Cancer Cells Antiandrogen Hydroxyflutamide in Androgen Activation of Mitogen-activated Protein Kinase Pathway by the Updated (2002) (1)
Intravesical Coxsackievirus A21 Therapy for Non-Muscle Invasive Bladder Cancer (2020) (1)
DEVELOPMENT AND VALIDATION OF A NOMOGRAM FOR PREDICTING PIRADS 4‐5 LESIONS ON MULTIPARAMETRIC PROSTATE MRI: MP08‐14 (2017) (1)
767 INDOCYANINE GREEN (ICG): A NOVEL APPROACH TO PELVIC LYMPH NODE IDENTIFICATION IN RADICAL CYSTECTOMY SPECIMENS (2011) (1)
MP22-07 BLADDER CANCER SCREENING: USE OF THE PLCO AND NLST TO IDENTIFY A SUITABLE SCREENING COHORT (2014) (1)
1281 INCIDENCE OF BLADDER CANCER AS A SECONDARY MALIGNANCY IN PATIENTS TREATED WITH RADIATION FOR CERVICAL CANCER (2012) (1)
Complete Remission of Locally Advanced Penile Squamous Cell Carcinoma after Multimodality Treatment (2016) (1)
Psychological Stress and Suicide in Bladder Cancer Patients (2018) (1)
110 NEOADJUVANT CHEMOTHERAPY AS A PREDICTOR OF COST, READMISSION, AND LENGTH OF STAY IN RADICAL CYSTECTOMY PATIENTS (2010) (1)
Continuous bladder infusion methods for studying voiding function in ambulatory mice. (2001) (1)
Robotic system for image-guided prostate seed implant (2008) (1)
Characteristics and outcomes of elderly patients with systemic prostate cancer (PCa) treated with peripheral androgen blockade (PAB). (2013) (1)
ANTIBIOTIC PROPHYLAXIS PRIOR TO URINARY CATHETER REMOVAL AFTER RADICAL PROSTATECTOMY DOES NOT PREVENT URINARY TRACT INFECTIONS: A RANDOMIZED CONTROLLED CLINICAL TRIAL: PD05‐10 (2017) (1)
284: Monitoring Superficial Bladder Cancer (BC) with the Immunocyt Fluorescent Cytology Test (2004) (1)
846: Diagnosis of Bladder Cancer Using a Point of Care Proteomic Assay: A Multicenter Study (2005) (1)
PSA-detected prostate cancer in the United States: A population-based study of 70,345 men with AJCC stage T1cN0M0 disease. (2013) (1)
677P A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Final analysis (2020) (1)
Pelvic implantation with three-dimensional, computed tomography-based preplanning (1990) (1)
SU‐FF‐T‐204: In Vivo Force‐Torque Measurement During Prostate Brachytherapy (2005) (1)
Use of Angiotensin Converting Enzyme Inhibitors and Risk of Late Bladder Toxicity Following Radiotherapy for Prostate Cancer. (2021) (1)
Review article Gender, racial and age differences in bladder cancer incidence and mortality (2004) (1)
37: Utilization and Cost-Effectiveness of Same Day Intravesical Chemotherapeutic Instillation Following Transurethral Resection of Newly Diagnosed Bladder Cancer (2006) (1)
SYMPTOMATIC LYMPHOCELE FORMATION AFTER EXTRAPERITONEAL VS. TRANSPERITONEAL ROBOT ASSISTED RADICAL PROSTATECTOMY AND BILATERAL PELVIC LYMPHADENECTOMY: MP64‐08 (2017) (1)
MP49-07 CANONICAL WNT PATHWAY TUMOR PROGRESSION IS MEDIATED BY THE LONG NON-CODING RNA HOTAIR IN BLADDER CANCER (2015) (1)
BCG INTERNALIZATION RELEASES INCREASED LEVELS OF IMMUNE‐ACTIVE EXTRACELLULAR VESICLES: MP65‐20 (2018) (1)
A prospective clinical trial of difluoromethylornithine (DFMO) in patients with resected superficial bladder cancer. (1992) (1)
N+, M0 prostate cancer: local therapy for systemic disease. (2013) (1)
Human bladder permeability assessment using intravesical fluorescein clearance rate. (2001) (1)
Perioperative Blood Transfusions and Bladder Cancer Outcomes (2018) (1)
IMPACT OF GLEASON PATTERN 4 CRIBRIFORM ARCHITECTURE ON PROSTATE CANCER DETECTION USING MULTIPARAMETRIC MRI: PD11‐10 (2017) (1)
A multivariate analysis of prognostic factors from assure (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma. (2016) (1)
1900 NON-BLADDER CANCER MORTALITY IN PATIENTS WITH UROTHELIAL CANCER OF THE BLADDER (2011) (1)
ESTROGEN RECEPTOR &agr; IN CANCER ASSOCIATED FIBROBLASTS SUPPRESSES PROSTATE CANCER INVASION VIA REDUCING CCL5, IL6 AND MACROPHAGE INFILTRATION IN THE TUMOR MICROENVIRONMENT.: MP87‐13 (2017) (1)
A PHASE III BLINDED STUDY OF IMMEDIATE POST‐TURBT INSTILLATION OF GEMCITABINE VERSUS SALINE IN PATIENTS WITH NEWLY DIAGNOSED OR OCCASIONALLY RECURRING GRADE I/II NON‐MUSCLE INVASIVE BLADDER CANCER: SWOG S0337: PNFLBA‐10 (2017) (1)
Abstract 152: The long non-coding RNA HOTAIR affects exosome-mediated bladder cancer progression (2015) (1)
Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer (2015) (1)
MP28-05 EXOSOMES PROMOTE BLADDER CELL MALIGNANT TRANSFORMATION, A NEW MECHANISM FOR THE FILED EFFECT (2014) (0)
PD37-04 PROTEIN DISULFIDE ISOMERASE IN EXTRACELLULAR VESICLES DRIVE MALIGNANT TRANSFORMATION IN BLADDER CANCER TUMOR MICROENVIRONMENT (2021) (0)
MP57-16 TUMOR DERIVED EXTRACELLULAR VESICLES PROMOTE BLADDER TUMORIGENESIS BY INDUCING ENDOPLASMIC RETICULUM STRESS. (2019) (0)
MP14-18 AN ANATOMIC CLASSIFICATION SYSTEM FOR LOCAL RECURRENCE FOLLOWING RESECTION OF INTERMEDIATE AND HIGH RISK NON-METASTATIC RENAL CELL CARCINOMA: AN ANALYSIS OF THE ASSURE (ECOG-ACRIN 2805) TRIAL (2019) (0)
An exploratory analysis of the R250W polymorphism in the KLK2 gene as a prognostic marker in prostate cancer (2007) (0)
PD18-03 COMPARISON OF SURVEILLANCE REGIMENS FOR LOW RISK NON-MUSCLE INVASIVE BLADDER CANCER: A PILOT STUDY (2019) (0)
Iatrogenic Causes of Urothelial Cancer of the Upper Urinary Tract and Bladder (2021) (0)
Seminar article Markers of detection (2007) (0)
MP19-01 MULTISPECTRAL PHOTOACOUSTIC IMAGING DIFFERENTIATES RENAL CELL CARCINOMA FROM ONCOCYTOMA (2016) (0)
EXTRACELLULAR VESICLES AS A POSSIBLE MECHANISM FOR BACILLUS CALMETTE‐GUÉRIN IMMUNOTHERAPY: MP65‐01 (2017) (0)
An unusual cause of an enhancing retroperitoneal mass. (2012) (0)
444: The Von Hippel-Lindau Tumor Suppressor Promotes TNF-A-Induced Renal Carcinoma Cell Apoptosis by Binding Casein Kinase 2A and Impairing NF-KB Survival Signaling (2007) (0)
Review article The timing of hormone therapy for men with asymptomatic advanced prostate cancer (2003) (0)
MP80-09 IS EXTRAPERITONEAL ROBOT-ASSISTED RADICAL PROSTATECTOMY CONTRAINDICATED IN THE SETTING OF PRIOR INGUINAL HERNIA REPAIR WITH MESH? (2016) (0)
A cross-sectional study of angiopoietin-1 (Ang-1) in early and advanced prostate cancer (2008) (0)
1 As submitted to : International Journal of Computer Assisted Radiology and Surgery and later published as : “ Radioactive seed immobilization techniques for interstitial brachytherapy ” (2018) (0)
Editorial Comment. (2015) (0)
Words of Wisdom. Re: potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. (2011) (0)
Abstract 1486: Bladder cancer exosomes contain tumor-associated mRNA and long non-coding RNA and facilitate tumor progression (2014) (0)
Role of Pelvic Radiation in Management of Non-Metastatic Pathological Node-Positive Prostate Cancer: A Single Institution Experience. (2021) (0)
ESTROGEN RECEPTOR &bgr; PROMOTES RENAL CELL CARCINOMA PROGRESSION VIA REGULATING LNCRNA HOTAIR‐MIR‐138/200C/204/217 ASSOCIATED CERNA NETWORK: MP88‐10 (2018) (0)
MP34-04 BURNOUT AND DOCUMENTATION BURDEN AMONG UROLOGY RESIDENTS AND ATTENDINGS AT THE UNIVERSITY OF ROCHESTER (2021) (0)
476 CAPTURE AND ANALYSIS OF PROSTATE CANCER STEM CELLS USING A MICROCIRCULATORY CHANNEL (2012) (0)
Editorial Commentary (2020) (0)
MP68-13 ESTROGEN RECEPTOR ALPHA PREVENTS BLADDER CANCER VIA INPP4B INHIBITED AKT PATHWAY IN VITRO AND IN VIVO (2015) (0)
Re: Use of 5α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline (2009) (0)
HF02-09 THE EVOLUTION OF THE DIAGNOSTIC LANDSCAPE OF RENAL MASSES (2022) (0)
A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Tolerability and geriatric asssessment (GA) results. (2019) (0)
Intraoperative treatment planning and guidance for prostate brachytherapy: results of a prospective randomized study (2001) (0)
TKI-INDUCED TREATMENT RESISTANCE OF RCC VIA MODULATING THE LONG NON-CODING RNA-ECVSR/ER Β /HIF2- a SIGNALING (2022) (0)
Preventing Bladder Recurrences after Nephroureterectomy for Upper Track Urothelial Cancer (2019) (0)
Chapter 7 – Prostate Cancer in the Elderly (2016) (0)
VALIDATION OF GEMCAP AS A DNA BASED BIOMARKER TO PREDICT PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY: PD71‐05 (2017) (0)
Paper Alert (2015) (0)
MP2-14 EFFICACY AND SAFETY OF A CLINICAL PROTOCOL FOR PREVENTING VENOUS THROMBOEMBOLISM AFTER SURGERY FOR UROLOGIC CANCER WITH IN HOSPITAL AND EXTENDED LOW MOLECULAR WEIGHT HEPARIN PROPHYLAXIS (2014) (0)
A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa). (2017) (0)
MP68-01 THE LONG NON-CODING RNA HOTAIR MODULATES EXOSOME CONTENT AND FUNCTION IN BLADDER CANCER TUMOR PROGRESSION (2015) (0)
PD42-10 ROLE OF EXTRACELLULAR VESICLE-BORNE PROTEIN DISULFIDE ISOMERASE IN BLADDER TUMORIGENESIS (2020) (0)
INFLUENCE OF SERUM TESTOSTERONE LEVEL AND BODY MASS INDEX ON SURVIVAL IN MEN TREATED WITH IMMEDIATE VERSUS DEFERRED ANDROGEN DEPRIVATION FOR NODE-POSITIVE PROSTATE CANCER AFTER PROSTATECTOMY AND PELVIC LYMPHADENECTOMY (2009) (0)
Open vs Robotic Surgery (2022) (0)
MP83-05 GLYCOLYTIC AND INFLAMMATORY PATHWAY GENES ARE OVEREXPRESSED IN BLADDER CANCER TUMORS (2016) (0)
Paper Alert Smoking Cessation in Bladder Cancer Patients (2019) (0)
DO OUTCOMES FROM SQUAMOUS CELL AND UROTHELIAL CARCINOMA OF THE BLADDER DIFFER WHEN ADJUSTING FOR STAGE (2009) (0)
Active Surveillance of Small Renal Masses: A Systematic Review (2021) (0)
PD17-12 FREQUENCY OF DOWNGRADING FROM MR/US FUSION BIOPSY TO RADICAL PROSTATECTOMY BASED ON ISUP 2014 GRADING MODIFICATIONS (2019) (0)
Editorial Comment. (2016) (0)
LOW TOXICITY AND HIGH ANTICANCER EFFICACY OF A NOVEL VITAMIN E ETHER ANALOG IN PRECLINICAL PROSTATE CANCER ANIMAL MODELS (2008) (0)
PD46-12 PRECLINICAL STUDIES USING CISPLATIN/CARBOPLATIN TO RESTORE THE ENZALUTAMIDE SENSITIVITY VIA DEGRADING THE ANDROGEN RECEPTOR SPLICING VARIANT 7 (ARV7) TO FURTHER SUPPRESS ENZALUTAMIDE RESISTANT PROSTATE CANCER (2022) (0)
MP53-07 PREDICTORS OF IPSILATERAL EXTRAPROSTATIC EXTENSION ON RADICAL PROSTATECTOMY USING 3-TESLA MULTIPARAMETRIC MRI AND CONTEMPORARY PATHOLOGIC FEATURES (2018) (0)
MP33-05 THE MAO INHIBITORS PHENELZINE AND CLORGYLINE REVERT ENZALUTAMIDE RESISTANCE IN CASTRATION RESISTANT PROSTATE CANCER (2021) (0)
Three-Dimensional Sonoelastography for In Vitro Detection of Prostate Cancer (2005) (0)
SU‐FF‐T‐52: A Robotic Platform for Image‐Guided Brachytherapy (IGBT) (2006) (0)
New Salvage Treatments for Metastatic Bladder Cancer (2020) (0)
Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis. (2022) (0)
MP34-02 ESTROGEN RECEPTOR ALPHA PREVENTS BLADDER CANCER VIA INPP4B/AKT PATHWAY: IN VIVO KNOCKOUT MOUSE EVIDENCE AND HUMAN TISSUE ANALYSIS (2014) (0)
Words of wisdom. Re: Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 clinical practice guideline. Kramer BS, Hagerty KL, Justman S, et al. (2009) (0)
Re: Dipstick pseudohematuria: unnecessary consultation and evaluation. P. K. Rao, T. Gao, M. Pohl and J. S. Jones J Urol 2010; 183: 560-565. (2010) (0)
MP31-19 E-SELETIN LIGAND-1 CONTROLS CIRCULATING PROSTATE CANCER CELLS’ ROLLING AND ADHESION AND METASTASIS (2014) (0)
PD12-05 IMPROVING RATES OF INTRAVESICAL CHEMOTHERAPY FOR LOW GRADE BLADDER CANCER (2020) (0)
MP16-14 ER&bgr;-MEDIATED ALTERATION OF CIRCATP2B1 AND MIR-204-3P SIGNALING PROMOTES INVASION OF CLEAR CELL RENAL CELL CARCINOMA (2019) (0)
Laparoscopy and Robotics Complications Associated With Extraperitoneal Robot-assisted Radical Prostatectomy Using the Standardized (2013) (0)
Beyond Cisplatin – I (2016) (0)
Abstract B05: Urothelial carcinoma exosomes contain Del1/EDIL-3 and facilitate bladder cancer progression (2013) (0)
Paper alert (2003) (0)
Implementing a New Standard of Care (2022) (0)
Clinical Variables That Predict for Adverse Pathological Features in Intermediate Risk Prostate Cancer (2017) (0)
Use of loop double-lumen drainage system to prevent postoperative urinary diversion leaks. (1986) (0)
Robot-assisted platform for intratumoral delivery (RAPID) (2007) (0)
PD2-11 OVERALL SURVIVAL AFTER PARTIAL VERSUS RADICAL NEPHRECTOMY FOR A SMALL RENAL MASS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES (2014) (0)
MP08-05 PHASE 1a/b STUDY OF INTRAVESICAL INSTILLATION OF TARA-002 IN ADULTS WITH HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER (2023) (0)
MP07-03 THE PROTECTIVE ROLE OF ESTROGEN RECEPTOR Β IN RENAL CALCIUM OXALATE FORMATION VIA REDUCING THE LIVER OXALATE BIOSYNTHESIS AND RENAL CELL INJURY (2021) (0)
EDITORIAL COMMENT. (2020) (0)
Increased risk of high-grade prostate cancer among testicular cancer survivors (2022) (0)
PD43-07 TKI-INDUCED TREATMENT RESISTANCE OF RCC VIA MODULATING THE LONG NON-CODING RNA-ECVSR/ERΒ/HIF2-α SIGNALING (2022) (0)
MP54-19 PROTEIN DISULFIDE ISOMERASE AS A PREDICTIVE BIOMARKER FOR NON-MUSCLE INVASIVE BLADDER CANCER RECURRENCE (2022) (0)
Editorial Comment. (2016) (0)
TRAIL-coated leukocytes to kill circulating tumor cells in the flowing blood from prostate cancer patients (2021) (0)
Editorial comment. (2012) (0)
MP13-12 MODERATE CHRONIC KIDNEY DISEASE (EGFR <60 ML/MIN) PREDICTS RECURRENCE AND PROGRESSION IN BLADDER CANCER PATIENTS TREATED WITH TRANSURETHRAL RESECTION (2016) (0)
Paper Alert (2016) (0)
RE: EDITORIAL: INTERSTITIAL CYSTITISA LIGHT AT THE END OF THE TUNNEL? (2000) (0)
Follow-up: recontacting subjects in mutagen exposure monitoring studies. (1988) (0)
1196 CIRCULATING ROLLING PROSTATE CANCER CELLS POTENTIATE METASTASIS: A MICRO-CHANNEL MODEL (2010) (0)
List of Speakers (2011) (0)
MP49-18 IDENTIFICATION OF EXTRACELLULAR VESICLE PERIOSTIN AS A URINARY BIOMARKER OF MUSCLE INVASIVE BLADDER CANCER (2015) (0)
The Significance of Immune Cytological Diagnostics for Bladder Carcinoma (1991) (0)
CLINICAL UROLOGY: Letters to the EditorRE: EDITORIAL: INTERSTITIAL CYSTITIS—A LIGHT AT THE END OF THE TUNNEL? (2000) (0)
912: Near Infrared Fluorescence of Intravenous Indocyanine Green for Intraoperative Imaging of Renal Cortical Tumors (2007) (0)
Interstitial cystitis--a light at the end of the tunnel? (1999) (0)
THE PROSTATIC EPITHELIAL SPECIFIC ANDROGEN RECEPTOR KNOCKOUT TRAMP MICE: AN ANIMAL MODEL FOR ANDROGEN INDEPENDENT PROSTATIC TUMOR (2008) (0)
Interstitial cystitis. (1994) (0)
MP16-04 TARGETING NEWLY IDENTIFIED ER&bgr;/TGF-&bgr;1/SMAD3 SIGNALS WITH THE FDA-APPROVED ANTI-ESTROGEN FASLODEX OR AN ER&bgr; SELECTIVE ANTAGONIST IN RENAL CELL CARCINOMA (2019) (0)
Re: Elective Nephron Sparing Surgery Decreases Other Cause Mortality Relative to Radical Nephrectomy Only in Specific Subgroups of Patients with Renal Cell Carcinoma. (2017) (0)
BCG versus Cystectomy for High Risk, High Grade Non Muscle Invasive Bladder Cancer (2021) (0)
MP20-10 ENZALUTAMIDE INCREASES PROSTATE CANCER (PCa) CELL INVASION YET DECREASES BLADDER CANCER (BCa) CELL INVASION VIA DIFFERENTIALLY REGULATING THE AR/circRNA-ARC1/miR-125b-2-3p OR MiR-4736/PPARγ/MMP-9 SIGNALS (2023) (0)
PD37-03 MULTI-INSTITUTIONAL MACHINE LEARNING TOOL FOR PREDICTING HIGH RISK LESIONS ON 3 TESLA MULTIPARAMETRIC PROSTATE MRI (2018) (0)
Paper Alert Implementing a New Standard of Care (2022) (0)
A Real-time Cancer Sensing Technique using Needle Insertion Forces and Patient-specific Criteria during Percutaneous Intervention (2008) (0)
CANCER EXTRACELLULAR VESICLES PROMOTE BLADDER TUMORIGENESIS BY INDUCING CHRONIC ENDOPLASMIC RETICULUM STRESS AND INFLAMMATION: A NOVEL MECHANISM FOR FIELD CANCERIZATION: MP65‐02 (2017) (0)
Is there a favorable subset of patients with metastatic prostate cancer who have oligometastases (2002) (0)
1705: Non-Invasive Uroflow Measurement in Mice (2004) (0)
BLADDER CANCER EXTRACELLULAR VESICLES FACILITATE METASTASIS: MP65‐18 (2018) (0)
A More Thorough Transurethral Resection (2017) (0)
1715: Early Detection and Measurement of Urothelial Tumors in Mice Using Computed Tomography (2005) (0)
2870 : In Vivo Measurement of Surgical Needle Intervention Parameters During Prostate Brachytherapy (2006) (0)
1583 LOSS OF EPITHELIAL OESTROGEN RECEPTOR α INHIBITS OESTROGEN-STIMULATED PROSTATE PROLIFERATION AND SQUAMOUS METAPLASIA VIA IN VIVO TISSUE SELECTIVE KNOCKOUT MODELS (2012) (0)
Interstitial cystitis. (1991) (0)
Impact of bladder cancer (BC) on health-related quality of life (HRQL) in 1,476 older Americans. (2013) (0)
Early versus late hormonal therapy for prostate cancer (2004) (0)
Smoking Cessation in Bladder Cancer Patients (2019) (0)
Abstract 517: Protein disulfide isomerase as a predictive biomarker for non-muscle invasive bladder cancer recurrence (2022) (0)
Does Blue Light Cystoscopy Reduce Recurrences of Non-Muscle Invasive Bladder Cancer? (2023) (0)
Controversies Lymph Node Dissection for Prostate Cancer (2010) (0)
Risk of adverse pathological features for intermediate risk prostate cancer: Clinical implications for definitive radiation therapy (2021) (0)
Changes in health-related quality of life (HRQL) after bladder cancer (BC) diagnosis (DX): A longitudinal population-based study. (2014) (0)
Editorial Comment. (2017) (0)
Phase I II S tudy o f I nterferon A lfa-NL a s A djuvant T reatment for R esectable R enal C ell C arcinoma: A n E astern C ooperative Oncology G roup/Intergroup T rial (2003) (0)
1284 BLADDER CANCER AS A SECONDARY MALIGNANCY AFTER RADIATION THERAPY FOR PRIMARY UTERINE CANCER (2013) (0)
EXTRAPERITONEAL VS. TRANSPERITONEAL ROBOT‐ASSISTED RADICAL PROSTATECTOMY IN THE MORBIDLY OBESE: MP93‐14 (2017) (0)
1915 PROSTATE-SPECIFIC ANTIGEN TESTING IN OLDER MEN IN THE UNITED STATES DATA FROM THE BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM (2012) (0)
Paper Alert (2016) (0)
Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study (2023) (0)
MP73-07 INTRAVESICAL CHEMOTHERAPY FOR LOW GRADE BLADDER CANCER: A COST ANALYSIS (2020) (0)
MP66-20 BLADDER CANCER EXTRACELLULAR VESICLES: A NOVEL ANTI-TUMOR VACCINE (2021) (0)
891 VITAMIN D AND BCG IMMUNOTHERAPY (2012) (0)
Antibiogram Directed Prophylaxis for Transrectal Prostate Biopsy: An Application of Recommendations in the Setting of High Fluoroquinolone Escherichia coli Resistance (2017) (0)
1130 UROTHELIAL CARCINOMA EXOSOMES PROMOTE CANCER PROGRESSION (2013) (0)
TARGETING ESTROGEN/ESTROGEN RECEPTOR SIGNAL PATHWAYS TO ENHANCE THE EFFICACY OF BACILLUS CALMETTE‐GUÉRIN TREATMENT IN BLADDER CANCER: MP65‐12 (2017) (0)
HGT1 bladder cancer (2015) (0)
Automated Urinalysis Machines: Potential Impact on the Diagnosis of Bladder Cancer (2019) (0)
V13-02 A NOVEL APPROACH TO INTRALUMINAL MITOMYCIN-C INSTILLATION FOR UPPER TRACT UROTHELIAL CARCINOMA (2021) (0)
MP17-19 RECRUITED T CELLS PROMOTE THE BLADDER CANCER METASTASIS VIA UP-REGULATION OF THE ESTROGEN RECEPTOR β/IL-1/C-MET SIGNALS (2020) (0)
1186 RENAL FUNCTION AFTER NEPHRON-SPARING SURGERY VS. RADICAL NEPHRECTOMY: DATA FROM THE EORTC TRIAL 30904 (2013) (0)
Arsenic Induced Bladder Cancer (2020) (0)
646: RAS Association Domain Family (RASSF) Expression in Normal Human Tissues and Cancer Cell Lines (2005) (0)
PD17-07 COMBINATION THERAPY FOR TKI RESISTANT KIDNEY CANCER VIA BLOCKING ERΒ/CIRCRNA-DGKD/MIR-125-5P/VE-CADHERIN SIGNAL INDUCED VASCULOGENIC MIMICRY (2023) (0)
Paper alert. (2016) (0)
Editorial comment. (2014) (0)
Northeastern Section of the AUA 72nd Annual Meeting Abstracts (2020) (0)
Assessment of murine bladder permeability with fluorescein: validation with cyclophosphamide and protamine. (2001) (0)
PD09-03 EXTRACELLULAR VESICLES: A MECHANISM OF ACTION OF BACILLUS CALMETTE-GUERIN AND A POTENTIAL BIOMARKER (2021) (0)
Topical Instillations of Chemotherapy for Renal Pelvic Urothelial Cancer (2020) (0)
Paper alert. (2016) (0)
808PA phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa) (2017) (0)
823: Tocopherol Associated Protein Suppresses Prostate Cancer Cell Growth by Inhibition of the PI3 Kinase Pathway (2006) (0)
1194 CIRCULATING VITAMIN D3 AND INTRA-PROSTATIC CYP27B1 IN PROSTATE TUMORIGENESIS (2010) (0)
Legends in Urology. (2018) (0)
Reply by Authors. (2022) (0)
Characterization of the Host Immuno-Inflammatory State in Response to Radiation Therapy and Correlation with Patient Reported Toxicities In Prostate Adenocarcinoma, A Prospective Observational Trial (2019) (0)
MP17-02 TENASCIN C EXPRESSION IN BENIGN PELVIC LYMPH NODES CORRELATES WITH METASTATIC STATUS AND SURVIVAL (2020) (0)
ENZALUTAMIDE RESISTANCE RESULTS IN IMMUNOSUPPRESSIVE ALTERATIONS IN PROSTATE TUMOR IMMUNE MICROENVIRONMENT (2023) (0)
Editorial Comment: Anticoagulant Associated Hematuria (1995) (0)
Long-Term Outcomes of Low Dose Rate Prostate Brachytherapy at a Single Institution (2017) (0)
Activation of Mitogen-activated Protein Kinase Pathway by the Antiandrogen Hydroxyflutamide in Androgen Receptor-negative Prostate Cancer Cells 1 (2002) (0)
A rapid tumor marker assay detects NMP22 in urine (2005) (0)
MP39-11 ESTROGEN RECEPTOR Β PROMOTES RENAL CELL CARCINOMA MALIGNANCY AND TKI RESISTANCE VIA REGULATING LNCRNA AND CIRCRNA ASSOCIATED CERNA NETWORK (2021) (0)
Salvage for BCG Unresponsive and Recurrent Disease (2021) (0)
Chapter 30 – Urologic Concerns in Critical Care (2005) (0)
The timing of hormonal treatment for prostate cancer (2000) (0)
777: The Von Hippel-Lindau Protein-Interacting Deubiquitinating Enzyme 2 Deubiquitinates and Stabilizes Hypoxia-Inducible Factor-1α (2004) (0)
MP16-17 ESTIMATING RECURRENCE-FREE SURVIVAL OF NON-MUSCLE INVASIVE BLADDER CANCER AFTER INTRAVESICAL THERAPY: A CLINICAL-BASED RECURSIVE PARTITION ANALYSIS (2021) (0)
Design of a non-biohazardous perfused simulation Model for Transurethral Resection of Bladder Tumor (TURBT) using 3D Printing and Hydrogel casting. (2023) (0)
Validation of GEMCaP as a DNA based biomarker to predict disease recurrence in patients undergoing prostatectomy for prostate cancer. (2017) (0)
Optimal Perioperative Chemotherapy for Muscle Invasive Bladder Cancer (2022) (0)
Perioperative Intravesical Therapy (2009) (0)
1889 TRUE LYMPH NODE COUNT IN RADICAL CYSTECTOMY SPECIMENS (2011) (0)
Author reply (0)
2865 : An Image-Guided Robotic System for Prostate Brachytherapy (2006) (0)
MP69-13 EXTRAPERITONEAL VS. TRANSPERITONEAL ROBOT-ASSISTED RADICAL PROSTATECTOMY IN THE SETTING OF PRIOR ABDOMINAL OR PELVIC SURGERY (2016) (0)
Do prostate cancer patients at risk of pelvic lymph-node metastasis benefit from pelvic radiation? (2006) (0)
357: Interstitial Cystitis Anti-Proliferative Factor (APF) as a Cell-Cycle Modulator (2004) (0)
GENDER AND RACIAL DIFFERENCES IN BLADDER CANCER MORTALITY: HOW MUCH OF A ROLE DO TUMOR FACTORS AT PRESENTATION PLAY? (2008) (0)
Early Detection of Urologic Cancer by Hematuria Homescreening in Healthy Men Over Age 50 (1987) (0)
MP68-14 EXTRACELLULAR VESICLES AS BIOMARKERS AND DIAGNOSTICS IN BLADDER CANCER (2015) (0)
apid Communication ecreased Bladder Cancer Growth n Parous Mice (2008) (0)
1584 REDUCED PROSTATE BRANCHING MORPHOGENESIS IN STROMAL FIBROBLAST ESTROGEN RECEPTOR α KNOCKOUT, BUT NOT IN EPITHELIAL ESTROGEN RECEPTOR α KNOCKOUT MICE (2012) (0)
Paper Alert Antibiotics and BCG (2022) (0)
MP29-20 ERβ CAN PROMOTE RENAL CELL CARCINOMA PROGRESSION VIA TGFβ-1/SMAD3 PATHWAY (2014) (0)
598 VALPROIC ACID REDUCES TUMOR GROWTH IN A MOUSE MODEL OF SUPERFICIAL BLADDER CANCER (2013) (0)
High Incidence of Pathologic Upgrading and Upstaging in Clinically Unfavorable Intermediate-Risk Prostate Cancer (2016) (0)
Paper alert. (2022) (0)
PD47-08 URINARY EXOSOME CYTOKINE LEVELS CORRELATE WITH PELVIC LYMPH NODE INFLAMMATION (2020) (0)
MP08-14 EVALUATION OF THE UROVYSION™ TEST FOR PREDICTING RECURRENCE AND PROGRESSION IN PATIENTS RECEIVING BCG FOR HIGH GRADE NON-MUSCLE INVASIVE BLADDER CANCER (2018) (0)
Reply by Authors. (2022) (0)
1651: Non-Bladder Cancer Causes of Death Among Patients with Newly Diagnosed Bladder Cancer: A Competing Risks Analysis in a Population-Based Study (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Edward M. Messing?

Edward M. Messing is affiliated with the following schools:

University of Western Ontario
Stanford University
China Medical University
University of Colorado
University of Rochester

Edward M. Messing's Academic­Influence.com Rankings

Why Is Edward M. Messing Influential?

Edward M. Messing's Published Works

Published Works

What Schools Are Affiliated With Edward M. Messing?

Edward M. Messing's AcademicInfluence.com Rankings